taken from the 2005 National Inpatient Sample. One-way frequencies, summary statistics, table analysis, logistic regression, linear regression, and kernel density were all used to evaluate the data. We used exploratory data analysis to investigate patient outcomes. There were 5622 patients with pneumonia and a control group of 5600 patients. RESULTS: Pneumonia affects 1-2 year olds more than older children. Most of the patients had a Charlson number of 0, indicating non-severe conditions. Out of 5622 patients, there were 73 fatalities. The majority of patients had a hospital expense of $2,000 to $12,000. Sex did not play a huge factor in the distribution of patient deaths. The mean age was 7.29 years old. The mean length of stay was 9.41 days. Patient procedure and diagnosis codes were analyzed to discover which codes had the most signifi cant impact on patients, length of stay, and total hospital charges. Patients with additional diseases were analyzed to see if there was a signifi cant difference in hospital length of stay and total hospital charges. CONCLUSIONS: Patients have different hospital costs, lengths of stay, initial diagnosis, procedures and outcomes according to their sickness, and how they can be treated. Most patients that come into the hospital do not have to stay too long, have a moderate hospital expense, and are generally young children. Pneumonia is a serious illness, occasionally fatal, but it can usually be treated successfully. , 2004 and February 29, 2008. A combination of electronic data extraction and manual chart review was performed on each subject's medical record for patient characteristics, risk factors, antifungal use prior and post echinocandin, adverse drug reactions associated with echinocandins, microbiological eradication, clinical success, length of stay, total hospital cost, and echinocandin cost. All statistical tests were two-tailed with p-value of less than 0.05 considered statistically signifi cant. RESULTS: A total of 106 patients with at least one positive bloodstream or sputum culture for C. albicans or C. non-albicans were included. Treatment groups had similar baseline characteristics in all areas except more micafungin patients had renal failure (p 0.016), prior antifungal use (p 0.021) and post antifungal use (p 0.002). Treatment success rates were comparable among groups (74% micafungin compared to 64% caspofungin, p 0.279). Microbiological success was 54% vs. 45% (p 0.367) for micafungin vs. caspofungin, respectively. There was no difference in microbiological success between C. albicans and C. non-albicans for micafungin (p 0.802), however, a signifi cant difference was seen in the caspofungin patients (C. albicans 35% vs. 59% C. non-albicans, p 0.05). Total cost of patient care (p 0.027) and echinocandin overall cost (p 0.001) were signifi cantly lower in the micafungin group. Length of stay and mortality rates were comparable among groups. CONCLUSIONS: We found overall treatment success was non-inferior among micafungin and caspofungin therapies. The calibrated model was then applied to assess the CHC burdens from 2007-2040 under the current pegylated-interferon/ribavirin (P/R) treatment strategy. A scenario from a hypothetical new CHC regimen (NEW) was also assessed. This included: NEW available in 2011 (70% SVR) for genotype-1, treatment-naïve patients; P/R treatmentfailure patients (TFs) re-treated by NEW with 50% SVR; NEW not used to treat genotype-2/3 patients; P/R durations consistent with current treatment guidelines by genotypes and costs $28,000/48-week; diagnosis and treatment rates remain unchanged with NEW. All costs were converted into 2007 dollars using 3% discount rate. RESULTS: Under P/R, US CHC prevalence at 2040 is projected to be around 1.7 million. Overall CHC direct medical cost is about $6 billion a year under P/R, only 13% of which is treatment-related; the remaining 87% comes from managing the comorbidities and long-term consequences of advanced liver disease (ALD) among undiagnosed patients, diagnosed-but-never-treated patients, and TFs. Compared to P/R, NEW is projected to cure 351,448 more patients, prevent 23,444 more CHC incidences, avert 103,953 more ALD incidence, and prevent 39,929 more deaths from . CHC prevalence at 2040 under NEW is projected to be 335,000 fewer patients. CONCLUSIONS: A new CHC regimen may have a higher public health impact than P/R. Costs unrelated to current CHC treatment with P/R are the major burden of hepatitis C. CYP2B6 and efavirenz disposition, HLA-B*5701 and abacavir hypersensitivity, and UGT1A1 and atazanavir hyperbilirubinemia. Clinically significant and confi rmed pharmacogenomic relationships were identifi ed for three ART drugs. Out of 405 studies, 6/202 studies were identifi ed as relevant to CYP2B6 and efavirenz disposition (2RCTs, 1 nRCT and 3 pharmacokinetic studies). Three (3/118) studies were identifi ed for HLA-B*5701 and abacavir hypersensitivity (2 RCTs and 1 nRCT) and 2/85 studies for UGT1A1 and atazanavir hyperbilirubinemia (1RCT and 1nRCT). Studies (2/6) revealed that genotype and sex were identifi ed as predictive covariates of efavirenz disposition. Studies (2/3) across the world have consistently demonstrated that HLA-B*5701 predicts the likelihood of hypersensitivity reactions to abacavir. As a consequence, pharmacogenetic screening for HLA-B*5701 has entered routine clinical practice and is recommended in most guidelines before starting an abacavir containing regimen. Studies (1/2) show that polymorphisms at MDR1-3435 signifi cantly infl uence atazanavir plasma concentrations, although ATV plasma concentrations directly correlate with bilirubin levels, the risk of severe hyperbilirubinemia is further increased in the presence of the UGT1A1-TA7 allele. CONCLU-SIONS: Although the wider applicability of pharmacogenomic relationships is prevalent and its use in clinical practice is still limited. Pharmacogenomics can greatly contribute in taking more adequate therapeutic decisions and to optimise treatment for HIV/AIDS.
PIN4 US HEPATITIS-C BURDEN ASSESSMENT FROM A TRANSMISSION MODEL
Zhang H g , Mehra M, Dibello J Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA OBJECTIVES: Achieving sustained virologic response (SVR) could prevent further transmission of hepatitis C virus (HCV) and reduce chronic hepatitis C (CHC) incidence; we developed a compartment model to describe the dynamics of HCV transmission in the United States. METHODS: This population model was expressed by partial differential equations across compartments based on: injection-drug use, CHC infection, diagnosis, genotypes, treatment/re-treatment, SVR and disease progression. Model inputs were based on published sources. Model was calibrated from 2002-2006 and matched closely with CDC reports and other published literature. The calibrated model was then applied to assess the CHC burdens from 2007-2040 under the current pegylated-interferon/ribavirin (P/R) treatment strategy. A scenario from a hypothetical new CHC regimen (NEW) was also assessed. This included: NEW available in 2011 (70% SVR) for genotype-1, treatment-naïve patients; P/R treatmentfailure patients (TFs) re-treated by NEW with 50% SVR; NEW not used to treat genotype-2/3 patients; P/R durations consistent with current treatment guidelines by genotypes and costs $28,000/48-week; diagnosis and treatment rates remain unchanged with NEW. All costs were converted into 2007 dollars using 3% discount rate. RESULTS: Under P/R, US CHC prevalence at 2040 is projected to be around 1.7 million. Overall CHC direct medical cost is about $6 billion a year under P/R, only 13% of which is treatment-related; the remaining 87% comes from managing the comorbidities and long-term consequences of advanced liver disease (ALD) among undiagnosed patients, diagnosed-but-never-treated patients, and TFs. Compared to P/R, NEW is projected to cure 351,448 more patients, prevent 23,444 more CHC incidences, avert 103,953 more ALD incidence, and prevent 39,929 more deaths from . CHC prevalence at 2040 under NEW is projected to be 335,000 fewer patients. CONCLUSIONS: A new CHC regimen may have a higher public health impact than P/R. Costs unrelated to current CHC treatment with P/R are the major burden of hepatitis C. CYP2B6 and efavirenz disposition, HLA-B*5701 and abacavir hypersensitivity, and UGT1A1 and atazanavir hyperbilirubinemia. Clinically significant and confi rmed pharmacogenomic relationships were identifi ed for three ART drugs. Out of 405 studies, 6/202 studies were identifi ed as relevant to CYP2B6 and efavirenz disposition (2RCTs, 1 nRCT and 3 pharmacokinetic studies). Three (3/118) studies were identifi ed for HLA-B*5701 and abacavir hypersensitivity (2 RCTs and 1 nRCT) and 2/85 studies for UGT1A1 and atazanavir hyperbilirubinemia (1RCT and 1nRCT). Studies (2/6) revealed that genotype and sex were identifi ed as predictive covariates of efavirenz disposition. Studies (2/3) across the world have consistently demonstrated that HLA-B*5701 predicts the likelihood of hypersensitivity reactions to abacavir. As a consequence, pharmacogenetic screening for HLA-B*5701 has entered routine clinical practice and is recommended in most guidelines before starting an abacavir containing regimen. Studies (1/2) show that polymorphisms at MDR1-3435 signifi cantly infl uence atazanavir plasma concentrations, although ATV plasma concentrations directly correlate with bilirubin levels, the risk of severe hyperbilirubinemia is further increased in the presence of the UGT1A1-TA7 allele. CONCLU-SIONS: Although the wider applicability of pharmacogenomic relationships is prevalent and its use in clinical practice is still limited. Pharmacogenomics can greatly contribute in taking more adequate therapeutic decisions and to optimise treatment for HIV/AIDS.
PIN5 PHARMACOGENOMICS: APPLICABILITY IN ANTIRETRO VIRAL THERAPY (ART) IN HIV PATIENTS

PIN6 A DATA ANALYSIS OF INPATIENTS AFFECTED BY THE HUMAN PAPILLOMAVIRUS
Peercy DP y University of Louisville, Louisville, KY, USA OBJECTIVES: The human papillomavirus is the most common sexually transmitted disease in America. This virus will affect 6.2 million Americans this year. Most cases of HPV come from sexual contact or vaginal delivery from an infected mother. It is the objective of this study to gain more knowledge about HPV in order to be able to control or prevent the spreading of this virus. METHODS: A data set of over 22,000 pediatric patients from the 2005 National Inpatient Sample was used for analysis with SAS Enterprise Guide to examine different characteristics of HPV. From SAS, we were able to set up one way frequencies, pie charts, kernel densities, and logistic and linear regressions to compare and contrast different aspects of HPV. We also examined patient diagnosis and procedure codes. RESULTS: The most prominent age groups affected by HPV are young children and adolescents. This is a concern since there is a strong relationship to cervical cancer in later life. Although two types of the virus (16 and 18) are responsible for 70% of cervical cancers, less than 1% of the patients in our sample died with HPV. This virus is not costly to detect or treat with the majority of the patients charged around $5,000 from hospitalization with the virus. We found that 90% of patients with a URI also had HPV. We found many statistically signifi cant relationships between demographics, procedures, and diagnoses, and length of stay or total charges of the patient. CONCLUSIONS: Further research is still needed for doctors to be able to prevent or cure HPV. Trial medications are out on the market targeting young females, but surprisingly, more males have HPV because they are the carriers of this virus. We need to focus more time and money to fi nd a cure for HPV.
PIN7 EXPLORING CELLULITIS: WHO GETS IT AND HOW SERIOUS IS IT?
DeWilde KM University of Louisville, Louisville, KY, USA OBJECTIVES: Cellulitis is a skin infection caused by bacteria. In children, cellulitis most often occurs on the face, legs, arms, or around the area near the anus. It can usually be treated with antibiotics (oral or topical). However, if not treated, the infection can spread and cause far more serious conditions such as meningitis or blood clots in the legs. The objective of this paper is to explore the data of pediatric patients who have cellulitis and to compare the results to patients who do not have the disease. Basic variables such as age, race, and gender are examined along with recorded patient diagnosis and procedure codes. METHODS: The statistical software SAS was used to analyze and explore the data supplied by the National Inpatient Sample for 2005. The dataset contained 1287 patients with cellulitis and a control group of 1300 without cellulitis. Statistical methods used include one-way frequencies, kernel densities, summary statistics, table analyses, logistic regression, and linear regression. We also examined the most frequent patient diagnoses and procedures for the patients in the dataset. RESULTS: The patients represented by the data are all pediatric. About 63% of patients with cellulitis are male, with about 37% female. The age group with the highest concentration of patients is 0-3 with about 29% of the total. Only 0.08% of the patients with cellulitis actually died. In general, the disease is not fatal. The average
